NCT06018766View on ClinicalTrials.gov

LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome.

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 17, 2023

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions
Bronchiolitis Obliterans SyndromeChronic Lung Allograft DysfunctionLung Transplantation
Interventions
DRUG

LAM-001

LAM-001 administered via dry powder inhaler

DRUG

Placebo

Placebo administered via dry powder inhaler

Trial Locations (1)

94143

RECRUITING

University of California, San Francisco, San Francisco

Sponsors

Collaborators (1)

OrphAI Therapeutics
All Listed Sponsors
collaborator

OrphAI Therapeutics

INDUSTRY

lead

Steven Hays, MD

OTHER

NCT06018766 - LAM-001 in Lung Transplant Recipients With Bronchiolitis Obliterans Syndrome. | Biotech Hunter | Biotech Hunter